@entity417 of XXXX : what are the treatment options?

@entity1 @entity417 @entity1261 @entity5 @entity2590 @entity1307 @entity1583
@entity417 is a common complication in @entity1 with @entity1583 , with incidence rates ranging up to 63%. In @entity2590 , @entity417 is an essential feature of the disease. The decrease in hemoglobin may lead to several symptoms such as fatigue, exhaustion, and impaired quality of life, and it may worsen prognosis. Before the introduction of recombinant @entity1 @entity1307 (rHuEPO, @entity1307 alfa), red blood cell transfusions were the traditional treatment for improvement of Hb levels. Transfusions, however, are associated with several adverse events and risks, have only transient effects, and have a limited capacity to ameliorate the symptoms of @entity417 . @entity1307 alfa represents a physiologic treatment option, especially in the long-term treatment of @entity5 treatment-associated @entity417 , and is well tolerated, with response rates as high as 80%. @entity1307 alfa is less effective in the treatment of the @entity417 of @entity2590 , but appears to be synergistic with @entity1261 . However, not every @entity1 responds to @entity1307 alfa; to avoid unnecessary interventions and costs, predictors of response have been proposed. This article outlines the advantages and disadvantages of the two major treatment forms of @entity417 : transfusions and @entity1307 alfa. Representative studies on the efficacy of @entity1307 alfa in anemic @entity1 with @entity1583 as well as models to predict response to @entity1307 alfa treatment are summarized.
